SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.
Guggenheim 2nd Annual Healthcare Innovation Conference
Date: Tuesday, November 11, 2025
Fireside Chat Time: 1:30 p.m. ET
Stifel 2025 Healthcare Conference
Date: Wednesday, November 12, 2025
Fireside Chat Time: 11:20 a.m. ET
TD Cowen Immunology and Inflammation Virtual Summit
Date: Thursday, November 13, 2025
Fireside Chat Time: 12:30 p.m. ET
Jefferies London Healthcare Conference
Date: Wednesday, November 19, 2025
Fireside Chat Time: 3:00 p.m. GMT / 10:00 a.m. ET
Citi 2025 Global Healthcare Conference
Date: Wednesday, December 3, 2025
Fireside Chat Time: 9:45 a.m. ET
A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD), and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class profiles through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Dan Budwick
1AB
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$56.77 |
| Daily Change: | 2.06 3.77 |
| Daily Volume: | 360,003 |
| Market Cap: | US$3.070B |
November 10, 2025 November 10, 2025 October 08, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
